LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SB590885 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 4121 | 3694 | 1.1156 | 1.1926 |
| SK-BR-3 | PIK-93 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2696 | 3694 | 0.7299 | 0.5500 |
| SK-BR-3 | KIN001-043 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3028 | 3694 | 0.8198 | 0.6998 |
| SK-BR-3 | Alpelisib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2012 | 3694 | 0.5448 | 0.2417 |
| SK-BR-3 | Luminespib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1655 | 3694 | 0.4480 | 0.0804 |
| SK-BR-3 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1070 | 3694 | 0.2897 | -0.1834 |
| SK-BR-3 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1799 | 3694 | 0.4870 | 0.1454 |
| SK-BR-3 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3082 | 3694 | 0.8344 | 0.7241 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2021 | 3694 | 0.5473 | 0.2458 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2686 | 3694 | 0.7272 | 0.5455 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1718 | 3694 | 0.4651 | 0.1088 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1520 | 3694 | 0.4115 | 0.0195 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3159 | 3694 | 0.8552 | 0.7587 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1031 | 3694 | 0.2791 | -0.2010 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1405 | 3694 | 0.3804 | -0.0322 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1300 | 3694 | 0.3520 | -0.0795 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1476 | 963 | 3694 | 0.2607 | -0.2317 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1041 | 3694 | 0.2818 | -0.1965 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 852 | 3694 | 0.2306 | -0.2817 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2867 | 3694 | 0.7763 | 0.6273 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1595 | 3694 | 0.4319 | 0.0535 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3146 | 3694 | 0.8517 | 0.7530 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1842 | 3694 | 0.4986 | 0.1647 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2297 | 3694 | 0.6218 | 0.3699 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2119 | 3694 | 0.5738 | 0.2900 |